A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.
Overview
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer is a phase 2 interventional study registered as NCT05999994 by Eli Lilly and Company, with 105 participants planned, started 2020-01-22 and due to reach its primary completion in 2027-05. Interventions recorded: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) in Participants With Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Shares Vinorelbine, Docetaxel, Gemcitabine and the tag pipeline.
- TrialA Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialStudy of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAsian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Vinorelbine, Gemcitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.
- TrialA Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Shares Abemaciclib, Eli Lilly (incl. Loxo) and the tag pipeline.